Payment overview · 2025
General Payments
$173.11
11 reported records · 5 companies
Healthcare provider profile · identity verified
Kenneth E Baird, MD
Allopathic & Osteopathic Physicians|Family Medicine · CARROLLTON, TX · NPI 1194755256
Verified facts
What the public records show
CMS Open Payments records show Kenneth E Baird, MD received $173.11 in general payments during 2025 across 11 reported records.
AstraZeneca Pharmaceuticals LP accounted for 32.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Farxiga by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $56.07 | 32.4% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $54.08 | 31.2% | 4 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $30.92 | 17.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.01 | 9.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $15.03 | 8.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $173.11 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $56.07 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $54.08 | 4 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $30.92 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.01 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.01 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $15.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 48 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 417 | 110 |
| Levothyroxine Sodium | Levothyroxine Sodium | 411 | 100 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 345 | 92 |
| Lisinopril | Lisinopril | 231 | 61 |
| Metoprolol Succinate | Metoprolol Succinate | 204 | 52 |
| Trazodone Hcl | Trazodone Hcl | 189 | 35 |
| Amlodipine Besylate | Amlodipine Besylate | 178 | 48 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 153 | 24 |
| Omeprazole | Omeprazole | 143 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 142 | 36 |
| Alprazolam | Alprazolam | 139 | 23 |
| Gabapentin | Gabapentin | 139 | 31 |
| Losartan Potassium | Losartan Potassium | 138 | 30 |
| Metformin Hcl | Metformin Hcl | 130 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 125 | 37 |
| Meloxicam | Meloxicam | 124 | 30 |
| Bupropion Xl | Bupropion Hcl | 113 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 112 | 26 |
| Metformin Hcl Er | Metformin Hcl | 96 | 18 |
| Tramadol Hcl | Tramadol Hcl | 93 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 91 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 90 | 30 |
| Furosemide | Furosemide | 85 | 18 |
| Simvastatin | Simvastatin | 79 | 18 |
| Sertraline Hcl | Sertraline Hcl | 78 | 20 |
| Prednisone | Prednisone | 75 | 57 |
| Clonazepam | Clonazepam | 73 | 13 |
| Alendronate Sodium | Alendronate Sodium | 67 | 14 |
| Allopurinol | Allopurinol | 65 | 20 |
| Liothyronine Sodium | Liothyronine Sodium | 65 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 63 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 60 | 16 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 59 | 29 |
| Azithromycin | Azithromycin | 58 | 50 |
| Ondansetron Odt | Ondansetron | 57 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 56 | suppressed |
| Temazepam | Temazepam | 56 | suppressed |
| Potassium Chloride | Potassium Chloride | 55 | 14 |
| Ozempic | Semaglutide | 54 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 53 | 15 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 52 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 51 | 17 |
| Celecoxib | Celecoxib | 50 | 11 |
| Eliquis | Apixaban | 48 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 47 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 47 | suppressed |
| Finasteride | Finasteride | 44 | 11 |
| Ibuprofen | Ibuprofen | 44 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 44 | suppressed |
| Baclofen | Baclofen | 41 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 41 | suppressed |
| Famotidine | Famotidine | 40 | 13 |
| Progesterone | Progesterone, Micronized | 40 | 13 |
| Propranolol Hcl | Propranolol Hcl | 38 | suppressed |
| Spironolactone | Spironolactone | 38 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 37 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 37 | 28 |
| Methocarbamol | Methocarbamol | 37 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 37 | suppressed |
| Glipizide | Glipizide | 36 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 36 | suppressed |
| Pregabalin | Pregabalin | 36 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 35 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 35 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 34 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Levofloxacin | Levofloxacin | 32 | 22 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 31 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 31 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 30 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 29 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 29 | suppressed |
| Ezetimibe | Ezetimibe | 29 | suppressed |
| Glipizide Er | Glipizide | 29 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 29 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 21 |
| Lorazepam | Lorazepam | 28 | suppressed |
| Methylprednisolone | Methylprednisolone | 27 | 23 |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Anastrozole | Anastrozole | 26 | suppressed |
| Jardiance | Empagliflozin | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 25 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Etodolac | Etodolac | 24 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Fluconazole | Fluconazole | 24 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 16 |
| Glimepiride | Glimepiride | 23 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 23 | 11 |
| Carvedilol | Carvedilol | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Telmisartan | Telmisartan | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 16 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Naproxen | Naproxen | 18 | 12 |
| Fenofibrate | Fenofibrate,micronized | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Modafinil | Modafinil | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $173.11 · 11 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, ELIQUIS, FREESTYLE LIBRE 3, NURTEC ODT, VRAYLAR, XYOSTED | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error